# DESCRIPTION

- introduce Alzheimer disease and Aβ oligomers

## BACKGROUND OF THE INVENTION

- describe Alzheimer disease pathology
- discuss Aβ peptides and their role in AD
- summarize previous research on Aβ and AD

## SUMMARY OF THE INVENTION

- introduce antibody molecule recognizing Aβ oligomers
- describe diagnostic and therapeutic applications
- summarize methods for diagnosing and monitoring AD
- discuss therapeutic methods and substances reducing AβpE3
- outline pharmaceutical composition and method of treatment

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

- characterize antibodies in APP/PS1KI and 5xFAD mice
- describe staining patterns in sporadic and familial AD cases
- summarize immunostaining results in human AD cases
- describe antibody recognition of AβpE3-42 oligomers
- outline diagnostic method for detecting Aβ oligomers
- describe method of monitoring treatment efficacy
- outline method of predicting treatment efficacy
- define binding molecule capable of recognizing AβpE3 oligomers
- describe properties of binding molecules
- outline therapeutic potential of binding molecules
- list potential applications of binding molecules in amyloid-related disorders
- define antibody
- describe antibody fragments
- introduce monoclonal antibodies
- describe production of monoclonal antibodies
- specify CDRs and variable regions
- provide for variants of variable regions
- outline methods for antibody preparation
- describe immunoblotting analysis
- describe immunostaining and immunoisolation methods
- exemplify ELISA test
- describe characterization of antibodies
- describe composition comprising binding molecule
- describe pharmaceutical composition
- describe method of treating or preventing amyloid-related disorder
- describe preferred embodiments of binding molecules
- outline method of inhibiting Aβ-oligomerization
- detail pharmaceutical composition and administration
- contemplate binding substance characteristics and treatment method
- provide method for identifying agents for amyloid-related disorders
- define AβpE3
- describe thioflavin T aggregation assay
- determine rate of oligomerization and aggregation
- describe candidate agents
- describe nucleic acid molecules
- describe vectors and host cells
- describe diagnostic purposes
- relate to antibody molecule for diagnosis
- describe method of diagnosing disease
- relate to method of diagnosing familial Alzheimer disease
- relate to method of diagnosing sporadic Alzheimer disease
- describe method of monitoring efficacy of treatment
- relate to method of predicting efficacy of treatment
- define terms and provide explanations
- describe reference amount
- relate to kit comprising antibody molecule
- provide sequences and illustrate invention

### EXAMPLES

- generate antibodies
- perform western blot
- analyze dot blot results
- apply antibodies to brain samples
- describe antibody 9D5H6 recognition pattern
- demonstrate age-dependent accumulation of AβpE3
- establish sandwich ELISA for diagnosis
- discuss relevance of intraneuronal Aβ accumulations
- describe dot blot competition and ELISA competition
- perform immunostaining competition
- summarize implications of AβpE3-42 accumulation
- perform size-exclusion chromatography
- analyze binding properties of antibody 9D5
- investigate aggregation of Aβ peptides
- demonstrate rescue of behavioral deficits in mouse model
- discuss role of oligomeric Aβ species in AD
- evaluate reduction of Aβ peptides in plaques
- present experimental results
- discuss therapeutic mechanism
- describe AD-like pathology in non-human primates
- analyze microglia cell in Alzheimer brain
- report passive immunization with 2-48 antibody
- discuss implications of results

